Investors wary of Teva-Mylan merger

April 21, 2015 4:37 PM

55 0

Investors wary of Teva-Mylan merger

Share price falls short of Teva’s offer of $82

LOS ANGELES (MarketWatch) — One look at Mylan N.V..’s stock price on Tuesday morning and investors might get a clue as to what sort of chances Teva Pharmaceuticals Industries has of pulling off a union of two of the world’s top generic drug makers.

Read more

To category page

Loading...